Francesca Palandri: Prioritizing Anemia Matters in Myelofibrosis
Francesca Palandri, Hematologist at Sant’Orsola-Malpighi Polyclinic – Bologna University Hospital, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Clinical Lymphoma, Myeloma and Leukemia, adding:
“Prioritizing anemia matters in myelofibrosis.
Happy to share our latest subgroup analysis from the phase III SIMPLIFY-1 trial, now published in Clinical Lymphoma, Myeloma Leukemia.
We examined momelotinib vs. ruxolitinib in JAK inhibitor–naive myelofibrosis patients with anemia (Hb 10 g/dL).
Key Findings:
- Momelotinib achieved higher dual response rates (spleen reduction and transfusion independence) vs. ruxolitinib: 27% vs. 7%
- In patients with platelets 200 × 10⁹/L, momelotinib showed superior spleen response: 39% vs. 17%
- Transfusion independence correlated with significantly improved overall survival (HR 0.25–0.40)
Prioritizing transfusion independence in anemic MF patients and suggest momelotinib may be preferred in those with lower platelet counts.
Honored to serve as first author of this collaborative work together with an outstanding group of colleagues.
A big thank-you to all my colleagues at IRCCS Policlinico di Sant’Orsola – Azienda Ospedaliero Universitaria di Bologna.”
Title: Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1
Authors: Francesca Palandri, Nicolaas P M Schaap, Jerome Rey, Nikolas von Bubnoff, Andreas Reiter, Juan Carlos Hernandez-Boluda, Timothy Devos, Lars Nilsson, Bethan Psaila, Donal P McLornan, Bryan Strouse, Shiyuan Zhang, Bharat Patel, Jessica Lim, Dwaipayan Patnaik, Stephen T Oh
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy